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Abstract
Background: Follow-up of coeliac disease is recommended to prevent complications associated with unsuccessful
treatment.
Objective: The objective of this article is to evaluate the implementation and significance of long-term follow-up.
Methods: Medical data were collected from 585 and follow-up questionnaires sent to 559 current adult coeliac
disease patients diagnosed in childhood. Diagnostic features and adulthood health outcomes were compared
between those with and without adulthood follow-up.
Results: Of paediatric patients, 92% were followed up 6–24 months after diagnosis. A total of 235 adults responded
to the questionnaires a median of 18 years after diagnosis, and 25% of them reported regular follow-up. They were
diagnosed more recently than those without follow-up (median year 2001 vs 1995, p¼ 0.001), being otherwise
comparable at diagnosis. Those with follow-up were less often smokers (5% vs 16%, p¼ 0.042) and relatives of
coeliac patients (48% vs 66%, p¼ 0.018), and more often students (48% vs 28%, p¼ 0.005) and type 1 diabetics
(19% vs 4%, p¼ 0.001). Lack of follow-up was not associated with complications, ongoing symptoms, poorer
general health or dietary adherence. All completely non-adherent patients were without follow-up.
Conclusions: Most coeliac disease patients diagnosed in childhood were not followed up according to recommen-
dations in adulthood. The individual effect of this on long-term treatment outcomes varied markedly.
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Key Summary
Established knowledge on this subject
. Current guidelines recommend regular follow-up of coeliac disease to support patients’ dietary adherence
and to detect possible complications associated with unsuccessful treatment.
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. Implementation and significance of long-term follow-up are scarcely studied, especially in originally
paediatric patients after the transition to adult care.
New findings of this study
. Only 25% of patients diagnosed in childhood reported follow-up of coeliac disease in adulthood.
. Lack of follow-up was not associated with poorer long-term treatment outcomes in general, but all
patients not adhering to a gluten-free diet were without follow-up.
. The results support more personally tailored follow-up of coeliac disease.
Introduction
With a prevalence of approximately 1% to 2%, coeliac
disease is one of the most common chronic gastrointes-
tinal diseases.1,2 Achieving optimal treatment outcomes
is therefore important both for the patients and for
public health.3 Inadequately treated coeliac disease pre-
disposes to reduced quality of life and possibly severe
long-term complications.4,5 The only approved treat-
ment, a strict gluten-free diet, may be demanding to
maintain, especially in food-related social situations
and because of the expense and limited availability of
appropriate products.6,7 These challenges may lead to
dietary lapses, highlighting the role of health care in
supporting dietary adherence and preventing complica-
tions related to unsuccessful treatment.
In children, maintenance of a gluten-free diet is usually
the responsibility of parents and other caregivers. The
situation changes markedly in adolescence, when patients
themselves should take responsibility for the treatment.
Unfortunately, this change is realised in turbulent pub-
erty, which increases the risk of poor adherence to an
already challenging diet.8–10 Hence, supporting young
patients during the transfer to adult care would seem
particularly important for strengthening their everyday
copingwith coeliac disease.11Although present guidelines
recommend the regular monitoring of coeliac dis-
ease,12–15 there is a lack of evidence about the actual
implementation and significance of the follow-up of
paediatric patients into adulthood.16
We investigated the prevalence and associated fac-
tors of regular follow-up in a large and well-defined
cohort of adult coeliac disease patients diagnosed in
childhood. Furthermore, the significance of follow-up
for long-term treatment outcomes was evaluated.
Materials and methods
Patients and study design
The study was carried out at Tampere University and
Tampere University Hospital. The hospital is a tertiary
referral centre serving a catchment area of approxi-
mately one million people, including 120,000 children.
The comprehensive medical data of paediatric coeliac
disease patients diagnosed in 1966–2014 were collected
frommedical records (n¼ 1070) (Figure 1). Patients now
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Figure 1. Flowchart of the study.
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diagnosis were recorded (n¼ 585) and included in the
study. After excluding individuals who had died (n¼ 7)
or had missing contact information (n¼ 19), study ques-
tionnaires were sent to 559 patients (Figure 1).17 The
presence of follow-up in childhood 6–24 months, 5–10
years, and more than 10 years after diagnosis was col-
lected from the patient records. Furthermore, the
responders were divided into two groups based on the
self-reported follow-up of coeliac disease in adulthood
as follows: 1) regular follow-up (at least every three
years) and 2) no regular follow-up. All relevant informa-
tion collected from medical records and by question-
naires was compared between these groups based on
adulthood follow-up.
Register-based data
Clinical and histological presentation and haemoglobin
and coeliac disease autoantibody values at diagnosis
were collected along with adherence and response to
the gluten-free diet and follow-up visits to a physician
and dietician after diagnosis.
The main reason for suspicion of coeliac disease was
classified as (a) gastrointestinal, such as diarrhoea and
stomach pain; (b) extra-intestinal, including for example
rash, arthralgia and poor growth or (c) at-risk group
screening. The presence and severity of symptoms were
categorised retrospectively depending on their frequency
and burden to daily life as (a) no symptoms, (b) mild
(minor/occasional symptoms), (c) moderate (more fre-
quent/distracting symptoms) or (d) severe symptoms
causing for example school absence or visits to an emer-
gency room. Poor growth was defined based on Finnish
nationwide recommendations.18
Serum anti-reticulin and endomysium antibodies,
which resemble each other closely,19 have been mea-
sured in our setting since the 1980s by indirect immuno-
fluorescence. A titre of 1:5 is considered positive, and it
is further diluted up to 1:4000.20 Blood haemoglobin
values (g/l) at diagnosis were collected when available.
Anaemia was defined as a haemoglobin value lower
than the age- and sex-dependent reference value.
Histology results at the time of coeliac disease diag-
nosis were collected from the pathology reports. In our
clinical routine, at least four representative samples are
taken from the duodenum in each esophagogastroduo-
denoscopy. Before the mid-1980s, the biopsies were
taken by the Watson biopsy capsule. Morphological
lesion in coeliac disease is classified as partial, subtotal,
or total villous atrophy. In children, follow-up biopsies
are rarely needed.21
Adherence to a gluten-free diet approximately one to
two years after diagnosis was categorised as (a) strict
gluten-free diet, (b) only occasional lapses and (c) non-
adherence. Beneficial short-term response to treatment
was defined as clinical improvement and a decrease in
coeliac disease autoantibodies.
Questionnaires
In addition to follow-up, a specific study questionnaire
was used to collect information about patients’ current
sociodemographic and lifestyle characteristics, such as
employment, presence of children, family history of
coeliac disease, membership in Finnish coeliac socie-
ties, smoking and physical activity. Furthermore, self-
reported health and health concerns, ongoing coeliac
disease-related symptoms, adherence to a gluten-free
diet, and experience of daily life restrictions caused
by the diet were surveyed along with the presence of
coeliac disease–associated and other chronic
comorbidities.
General health was categorised as (a) excellent/good
or (b) moderate/poor, and health concerns as (a) none/
minor or (b) moderate/severe concerns. Dietary adher-
ence was classified as (a) strict diet, (b) occasional
lapses (lapses less than once a month) or (c) frequent
lapses or non-adherence (lapses monthly or more
frequently). Experience of maintaining the diet was
categorised as (a) easy, (b) somewhat difficult or
(c) difficult.
The Gastrointestinal Symptom Rating Scale (GSRS)
was used to evaluate the presence and severity of
gastrointestinal symptoms. Fifteen questions are
scored on a Likert scale from 1 to 7, with higher
scores indicating more severe symptoms. The total
score is calculated as the mean of all answers in add-
ition to five specific subgroup scores – including diar-
rhoea, indigestion, constipation, pain and reflux – as
means of two to four selected answers.22
The Psychological General Well-Being questionnaire
(PGWB) was used to evaluate health-related quality of
life. It contains 22 questions scored from 1 to 6, with a
higher score indicating better well-being and quality of
life. The total score is a sum of all questions, with the
range being 22–132. More detailed subgroup scores are
calculated as sums of two to four relevant questions for
anxiety, depression, positive well-being, self-control,
general health and vitality.23
Statistical analysis
Statistical analyses were performed with SPSS v25.0
(IBM Corp, Armonk, NY, USA). Categorical variables
are reported as percentages and numeric variables as
medians with lower and upper quartiles. Chi-square
and Fisher tests were used to assess significance in com-
parisons of ordinal or nominal variables, and the
Mann-Whitney test was used in comparisons of
numeric variables. Binary logistic regression was used
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to adjust the age difference between the study groups.
A p value less than 0.05 was considered significant.
Ethics
The study protocol conforms to the ethical guidelines
of the 1975 Declaration of Helsinki. The Department of
Paediatrics and the Regional Ethics Committee of
Tampere University Hospital approved the study
design and questionnaire process (ethics committee
code R16091, 31 May 2016). All participants answer-




At least one guidance visit after a coeliac disease diag-
nosis in childhood was arranged for all 585 now-adult
patients, and 92% had another follow-up visit 6–24
months later. Thereafter, based on the patient record
data, follow-up decreased gradually to 26% after more
than 10 years. Correspondingly, 25% of the now-adult
patients responding to the study questionnaires
reported regular follow-up (Figure 2).
Dietary counselling at the time of diagnosis was
given by a dietician in 63% and by another health-
care provider in 37% of cases. At 12–24 months after
the diagnosis, 85% of the patients reported a strict
gluten-free diet, 12% had occasional lapses, and 3%
did not adhere to the diet. Despite only partial
adherence in some patients, 99% reported a beneficial
dietary response.
Follow-up in adulthood
Altogether 235 (42%) of the now-adult patients
answered the questionnaires. The responders were
more often women (69% vs 52%, p< 0.001) and rela-
tives of coeliac disease patients (56% vs 44%,
p¼ 0.035), and they were less often co-existing type 1
diabetics (9% vs 16%, p¼ 0.029) when compared to the
non-responders. Based on the medical records, the
responders and non-responders did not differ with
respect to age and year of diagnosis, clinical presenta-
tion, severity of histopathology or selected laboratory
results (Table 1), presence of short-term follow-up, or
short-term dietary adherence and treatment response.
Furthermore, the presence of follow-up 5–10 years after
the diagnosis and current age were comparable (data
not shown).
Among the 235 now-adults responding to the ques-
tionnaires, the childhood coeliac disease diagnosis had
been established more recently in the 59 patients with
regular adulthood follow-up, whereas the follow-up
and no follow-up groups were comparable with respect
to sex, age, clinical presentation, severity of histological
damage and laboratory parameters as reported in the
patient records (Table 1).
Based on the current evaluation, the patients who
were followed up were younger and more often stu-
dents, but they were less often smokers and relatives
of coeliac disease patients. After adjustment for age,
the differences with respect to the presence of students,
current smokers and family history of coeliac disease
were no longer significant. The groups were also com-
parable with respect to employment status, presence of
children, physical activity and self-perceived health, as
well as with respect to experiences of and adherence to
a gluten-free diet (Table 2). However, all completely
non-adherent patients (n¼ 5) were without follow-up.
Lack of adulthood follow-up was not associated
with a higher severity of persistent gastrointestinal
symptoms or with a poorer quality of life as measured
by the GSRS and PGWB (Table 3). Coexisting type 1
diabetes was more common among patients with regu-
lar follow-up, whereas there were no differences in the
presence of other comorbidities or coeliac disease–
related complications (Table 4).
Regular follow-up comprised the evaluation of ser-
ology and contact with health-care providers in all
patients, but only 22 reported personal visits to a
doctor or nurse. In a subgroup analysis, fractures
were more common and a gluten-free diet was experi-
enced as more difficult to adhere to among patients














Figure 2. Presence of follow-up in children diagnosed with
coeliac disease (n¼ 585).
*Self-reported, data from questionnaires (n¼ 235).
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health-care contact, whereas the groups did not differ
with respect to other health-related outcomes or comor-
bidities (Table 5) or in the GSRS and PGWB scores
(data not shown).
Discussion
We found that almost all paediatric patients received
appropriate short-term monitoring of their coeliac
disease, but after this early period the frequency of
follow-up declined and was eventually reported only
by one-fourth of the sample in adulthood. To the best
of our knowledge, there are only a few previous studies
on this issue. In accord with us, O’Leary et al. found
only 11 (22%) out of 50 coeliac disease patients to
attend follow-up after a median of 29 years from the
childhood diagnosis.24 More recently, Norsa et al.
reported more positive results, with up to 83% of the
patients having regular follow-up 30 years after
childhood diagnosis.25 Studies focusing on patients
diagnosed in adulthood have reported long-term
follow-up in 15% to 73% of their sample.26–28 Taken
together, the follow-up of paediatric and adult coeliac
disease does not seem to meet recommendations.12–15
Follow-up was even less frequent when only per-
sonal health-care visits were counted, and a parallel
finding was reported in a US study investigating
short-term follow-up mainly in adults.28 In the present
study, the patients with personal contact reported more
fractures and found the gluten-free diet more difficult,
despite the comparability of their dietary adherence to
those with other forms of health-care contact. In the
best-case scenario, follow-up is focussed on those with
health issues and challenges with the treatment.
Notably, although caution is needed before drawing
excessively strong conclusions, the lack of direct
health-care contact did not seem to affect long-term
treatment outcomes negatively.
Other factors increasing the likelihood of long-term
follow-up were being a student and having a more
recent coeliac disease diagnosis. The Finnish Student
Health Service offers low-threshold health-care services
Table 1. Characteristics at the time of childhood coeliac disease diagnosis in 235 responders with and without regular follow-up
in adulthood and in 324 non-responders.
Regular adulthood follow-up
Non-responders, n¼ 324Yes, n¼ 59 No, n¼ 176 p valuea
Girls, % 68 71 0.700 52
Age, median (Q1, Q3), y 8.8 (5.6, 13.6) 9.7 (5.0, 13.7) 0.975 10.1 (6.3, 13.6)
Year of diagnosis, median (Q1, Q3) 2001 (1996, 2006) 1995 (1984, 2002) 0.001 1999 (1990, 2005)
Main clinical presentation, % 0.667
Gastrointestinal 53 53 45
Extra-intestinal 24 28 30
Screen-detected 24 19 25
Diarrhoea, % 39 50 0.161 40
Abdominal pain, % 49 42 0.411 48
Anaemia, % 27 29 0.796 23
Poor growth, % 37 47 0.177 39
Severity of symptomsb, % 0.506
None 34 29 30
Mild 38 38 40
Moderate 26 24 23
Severe 2 9 7
Degree of villous atrophy, % 0.352
Partial 37 30 33
Subtotal 42 38 36
Total 21 31 31
Ema/ARA, median (Q1, Q3), titre 1:200 (1:100, 1:1000) 1:500 (1:100, 1:1000)
c 0.356 1:500 (1:100, 1:1000)d
Haemoglobin, median (Q1, Q3), g/l 125 (120, 132)
e 123 (114, 131) 0.362 127 (118, 134)f
aComparison of patients with and without follow-up. Data available for> 80% of patients except in (n): b183, c116, d151, e44 and f225.
ARA: serum anti-reticulin antibodies; Ema: serum endomysium antibodies; Q1 and Q3: lower and upper quartiles.
Bold text states statistically significant p value.
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at a reasonable price for those studying at higher edu-
cation institutions.29 This easier access to health care
could play a significant role in the patients’ motivation
to attend follow-up. In our previous adult study, most
coeliac disease patients wanted regular follow-up, but
did not eagerly seek it if not prearranged by their health
care provider.26 In line with this, Hughey and col-
leagues reported the most common reason for neglect-
ing the follow-up to be the patients’ perception that
there was no strong need for it.27 The higher frequency
of follow-up in more recently diagnosed patients could
be due to better organisation in recent years or because
newer patients have not yet been lost to follow-up.
Herman et al.28 reported patients presenting with
diarrhoea more often having short-term follow-up,
but we did not observe a similar association. It is pos-
sible that the classical form of coeliac disease is con-
sidered to have a higher risk for complications and
therefore the need for follow-up is more intensive.
However, evidence on this is lacking; in fact, adherence
problems might be even more common among those
with mild or atypical presentation.30
Remarkably, lack of long-term follow-up was asso-
ciated neither with poor dietary adherence nor with
Table 2. Current sociodemographic and lifestyle characteristics, self-reported health, and gluten-free diet in 235
adult coeliac disease patients diagnosed in childhood and divided into those with and without regular follow-up.
Regular adulthood follow-up
Yes, n¼ 59 No, n¼ 176 p value p valuea
Age, median (Q1, Q3), y 22.8 (20.2, 28.5) 29.3 (22.9, 39.5) <0.001 –
Time from diagnosis (Q1, Q3), y 14.9 (10.7, 19.9) 20.6 (14.0, 32.3) 0.001 0.578
Working full time or part timeb, % 83 78 0.543 –
Student, % 48 28 0.005 0.270
Offspring, % 35 45 0.145
Coeliac disease in the family, % 48 66 0.018 0.061
Member of coeliac society, % 62 49 0.088 –
Smoking
Current, % 5 16 0.042 0.114
Quit, % 6 28 <0.001 0.011
Physical exercisec, % 56 61 0.461 –
Self-reported health, % 0.757 –
Excellent or good 83 81
Moderate or poor 17 19
Concerns about health, % 0.371 –
None or minor 86 81
Moderate or severe 14 20
Coeliac-related symptomsd, % 19 25 0.320 –
Perception of daily life restrictionse, % 55 44 0.138 –
Adherence to a gluten-free diet, % 0.702 –
Strict diet 83 77
Occasional lapses 12 14
Frequent lapses or non-adherence 5 9
Experience of the gluten-free diet, % 0.155 –
Easy 73 81
Somewhat difficult 27 17
Difficult 0 2
aAdjusted for current age.
bData available for more than 95% of patients except in n¼ 186.
cAt least half an hour, three times a week.
dSelf-assessment.
eCaused by coeliac disease.
Q1 and Q3: lower and upper quartiles.
Bold text states statistically significant p value.
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major long-term health problems, such as complica-
tions. A similar lack of association between the
strictness of the gluten-free diet and the presence of
follow-up was observed in our previous studies with
different designs.9,26 However, studies from Israel31
and Croatia32 have reported poorer adherence among
patients not followed up. It might be the case that
depending on the local circumstances, factors other
than the presence of regular follow-up play a more sig-
nificant role in the long-term success of the treatment,
including for example the availability and prices of
gluten-free products, individual knowledge about coel-
iac disease, and general attitudes toward the import-
ance of a strict diet.8,9,33 Educational training of
professionals, membership of coeliac societies and
information provided by physicians and dieticians for
patients are other factors that may affect compliance
with the diet.34 These country- and patient-related dif-
ferences are important to consider before implementing
our results in clinical practice.
It must be emphasised that although here the lack of
follow-up had no major influence on the long-term
treatment outcomes, there might be a subgroup of
patients who require special attention. In particular,
all the participants who reported complete non-
adherence to a gluten-free diet were without follow-
up, and smoking was more common among individuals
who were not followed up, indicating a generally less
healthy lifestyle. In fact, the proportion of such patients
could be even higher because these poorly motivated
individuals might also have been more prone to refuse
the study. These patients should be recognised and if
possible receive special support with dietary treatment,
keeping in mind that long-term poor compliance pre-
disposes them to severe complications such as osteopor-
osis and even intestinal lymphoma.4 Patients diagnosed
in adulthood may require particular attention because
they often have long diagnostic delay, and gluten-free
diet is likely less efficient to prevent the complications
and comorbidities.5
It is a challenge to predict which originally paediatric
patient needs special support in adulthood and to deter-
mine how these patients can be monitored. The transi-
tion to adult care could be an opportunity to recognise
those at risk for future challenges and to tailor the
Table 4. Comorbidities in 235 adult coeliac disease patients








Type 1 diabetes 19 4 0.001f
Hypo/hyperthyroidism 14 9 0.265
Other diseases
Allergya 39 43 0.587
Asthma 16 10 0.229
Cancerb 4 1 0.257
Depression 7 15 0.132
Dermatologic diseasec 18 15 0.612
Eating disorder 4 4 1.000
Gastrointestinal diseased 5 7 1.000
Hypertension 7 4 0.472
Osteoporosis 4 1 0.257
Rheumatic diseasee 4 4 1.000
Fracture(s) 23 25 0.755
Miscarriage(s) 5 12 0.248
aFor example, pollen, food, or medicines.
bFor example, cancer of central nervous system, breast cancer, or
Hodgkin lymphoma.
cFor example, atopic eczema, acne, or psoriasis.
dFor example, ulcerative colitis, Crohn disease, gastric ulcer, or irrit-
able bowel syndrome.
eFor example, rheumatoid arthritis, fibromyalgia, or Still disease.
fp¼ 0.001 when the groups were adjusted for current age.
Data available for 95% or more of patients in each variable.
Bold text states statistically significant p value.
Table 3. Current symptom and well-being scores in 235 adult
coeliac disease patients diagnosed in childhood and divided





Median (Q1, Q3) p value
GSRSa
Total 1.9 (1.4, 2.3) 1.9 (1.5, 2.4) 0.584
Diarrhoea 1.3 (1.0, 1.8) 1.3 (1.0, 2.0) 0.906
Indigestion 2.5 (1.8, 3.0) 2.3 (1.8, 3.3) 0.901
Constipation 1.3 (1.0, 2.0) 1.3 (1.0, 2.3) 0.530
Pain 2.0 (1.3, 2.3) 2.0 (1.3, 2.7) 0.581
Reflux 1.0 (1.0, 2.0) 1.3 (1.0, 2.0) 0.271
PGWBb
Total 107 (93, 112) 105 (93, 114) 0.955
Anxiety 24 (19, 26) 24 (20, 26) 0.549
Depression 17 (15, 18) 17 (15, 18) 0.874
Positive well-being 18 (15, 19) 18 (15, 20) 0.903
Self-control 16 (14, 17) 16 (14, 17) 0.806
General health 15 (12, 16) 14 (11, 16) 0.526
Vitality 18 (14, 20) 17 (15, 19) 0.727
Higher scores indicate either amore severe symptoms or bbetter qual-
ity of life.
Data available for 90% or more of patients in each variable.
GSRS: Gastrointestinal Symptom Rating Scale; PGWB: Psychological
General Well-Being; Q1 and Q3: lower and upper quartiles.
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subsequent follow-up according to personal needs, as
well as to ensure sufficient knowledge about coeliac dis-
ease before shifting the responsibility for treatment
onto the adolescents themselves.16 Thereafter, those
without difficulties could be seen less frequently com-
pared to the more problematic cases. Moreover, as
monitoring methods improve, the follow-up could also
be made easier, for example, by using practical fingertip
tests for antibodies35 and urine tests for the detection of
gluten immunogenic peptides – even at home.36 Health
care could then be obtained when there are compliance
problems or other health concerns. Because convenience
seems to be an important factor affecting the motivation
for follow-up,26,27 such methods could encourage
patients to further engage with their own treatment.
Strengths and limitations
The main strength of the present study is the large and
well-defined cohort of paediatric coeliac disease
patients. We also managed to collect comprehensive
adulthood follow-up data, and the use of validated
questionnaires for gastrointestinal symptoms and psy-
chological well-being enhances the comparability of the
results. Furthermore, the participants represented an
unselected population as opposed to selected
Table 5. Subgroup analysis of 59 regularly followed-up adult coeliac disease patients diagnosed in childhood with
personal visits to a doctor/nurse and other contact with health care.
Personal follow-up visits
Yes, n¼ 22 No, n¼ 37 p value
Women, % 68 68 0.961
Age, median (Q1, Q3), y 24.4 (19.7, 29.8) 22.1 (20.2, 29.7) 0.649
Time from diagnosis (Q1, Q3), y 15.0 (9.8, 21.1) 14.9 (11.6, 19.6) 0.888
Coeliac disease in the family, % 46 50 0.737
Member of coeliac society, % 64 61 0.847
Comorbidities/complications
Type 1 diabetes, % 32 11 0.081
Hypo/hyperthyroidism, % 19 11 0.443
Depression, % 15 3 0.125
Osteoporosis, % 10 0 0.119
Fractures, % 40 14 0.044
Miscarriage(s), % 5 3 1.000
Cancer, % 0 5 0.536
Self-reported health, % 0.729
Excellent or good 86 81
Moderate or poor 14 19
Concerns about health, % 0.462
None or minor 82 89
Moderate or severe 18 11
Coeliac-related symptomsa, % 32 11 0.081
Perception of daily life restrictionsb, % 67 49 0.185
Adherence to a gluten-free diet, % 0.080
Strict diet 73 89
Occasional lapses 14 11
Frequent lapses or non-adherence 14 0
Experience of the gluten-free diet, % 0.015
Easy 55 84
Somewhat difficult 46 16
Difficult 0 0
aSelf-assessment.
bCaused by coeliac disease. Data available for more than 95% of patients.
Bold text states statistically significant p value.
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recruitment, such as via patient organisations. On the
other hand, this probably explains the moderate
response rate, which may predispose to selection bias.
The risk for this was reduced by the similarity of the
responders and non-responders as regards the register-
based data. The fact that diagnostic and short-term
follow-up data were collected retrospectively and were
partly incomplete, especially in classification of the
severity of symptoms and some laboratory results, is
another limitation. Short-term dietary adherence and
treatment response were mainly reported by parents
of the paediatric patients. Also, we did not have data
about the causes of death in seven patients.
Conclusion
We found the long-term follow-up of paediatric coeliac
disease patients does not meet current recommenda-
tions.12–15 Although in the majority of cases this does
not seem to affect dietary adherence or other long-term
treatment outcomes, there might be a subgroup of
patients who experience significant coping challenges,
as all the non-adherent adult patients were without cur-
rent follow-up. These individuals, as well as those
experiencing persistent symptoms or with increased
risk for complications and comorbidities, should
receive particular attention. Together, these findings
support a more personalised approach to the long-
term monitoring of paediatric coeliac disease.
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Laura Kivelä, Katri Kaukinen and Kalle Kurppa have
received personal fees for lectures from the Finnish Coeliac
Society outside the submitted work and act as members of the
Finnish Coeliac Society’s advisory committee. All other
authors declare no conflict of interest.
Ethics approval
The study protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinki. The Department of Paediatrics
and the Regional Ethics Committee of Tampere University
Hospital approved the study design and questionnaire process
(ethics committee code R16091, 31 May 2016).
Funding
This work was supported by the Foundation for Paediatric
Research, the Competitive State Research Financing of the
Expert Area of Tampere University Hospital, the Maire Rossi
Foundation, the Maud Kuistila Foundation, the Mary and
Georg Ehrnrooth Foundation, the Paolo Foundation and the
Emil Aaltonen Foundation.
Informed consent






1. Mustalahti K, Catassi C, Reunanen A, et al. The preva-
lence of celiac disease in Europe: Results of a centralized,
international mass screening project. Ann Med 2010; 42:
587–595.
2. Rubio-Tapia A, Ludvigsson JF, Brantner TL, et al. The
prevalence of celiac disease in the United States. Am J
Gastroenterol 2012; 107: 1538–1544.
3. Haines ML, Anderson RP and Gibson PR. Systematic
review: The evidence base for long-term management of
coeliac disease. Aliment Pharmacol Ther 2008; 28:
1042–1066.
4. West J, Logan RFA, Smith CJ, et al. Malignancy and
mortality in people with coeliac disease: Population
based cohort study. BMJ 2004; 329: 716–719.
5. Paarlahti P, Kurppa K, Ukkola A, et al. Predictors of
persistent symptoms and reduced quality of life in treated
coeliac disease patients: A large cross-sectional study.
BMC Gastroenterol 2013; 13: 75.
6. Panagiotou S and Kontogianni MD. The economic
burden of gluten-free products and gluten-free diet: A
cost estimation analysis in Greece. J Hum Nutr Diet
2017; 30: 746–752.
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